Cargando…

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

INTRODUCTION: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should theref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sidana, Surbhi, Narkhede, Mayur, Elson, Paul, Hastings, Debbie, Faiman, Beth, Valent, Jason, Samaras, Christy, Hamilton, Kimberly, Liu, Hien K., Smith, Mitchell R., Reu, Frederic J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344345/ https://www.ncbi.nlm.nih.gov/pubmed/28278302 http://dx.doi.org/10.1371/journal.pone.0172996

Ejemplares similares

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
por: Faiman, Beth, et al.
Publicado: (2016)

Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma
por: Chakraborty, Rajshekhar, et al.
Publicado: (2020)

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
por: Dima, Danai, et al.
Publicado: (2023)

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
por: Hasan, Syed M., et al.
Publicado: (2018)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Should we measure clonal circulating plasma cells in light chain amyloidosis?
por: Sidana, Surbhi, et al.
Publicado: (2018)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

A dose increased once-weekly bortezomib-based combination therapy for multiple myeloma
por: Wei, Daolin, et al.
Publicado: (2016)

Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
por: Minarik, Jiri, et al.
Publicado: (2015)

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
por: Brennan, Xavier, et al.
Publicado: (2022)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians
por: Banerjee, Rahul, et al.
Publicado: (2023)

Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
por: Charaf, Edriss, et al.
Publicado: (2009)

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
por: Yamamoto, Shota, et al.
Publicado: (2021)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Effectiveness of Bortezomib in Cardiac AL Amyloidosis: A Report of Two Cases
por: Nigrelli, Santi, et al.
Publicado: (2014)

Ventricular Fibrillation after Bortezomib Therapy in a Patient with Systemic Amyloidosis
por: Yamasaki, Satoshi, et al.
Publicado: (2013)

The protective effects of lafutidine for bortezomib induced peripheral neuropathy
por: Tsukaguchi, Machiko, et al.
Publicado: (2013)

Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain
por: Zhi, W. Iris, et al.
Publicado: (2018)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Subcutaneous Administration of Bortezomib: Strategies to Reduce Injection Site Reactions
por: Kurtin, Sandra, et al.
Publicado: (2012)

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses
por: Martin, Jasmine R., et al.
Publicado: (2015)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
por: Jeter, Ashley, et al.
Publicado: (2012)

Characterization of a rat model of bortezomib‐induced painful neuropathy
por: Duggett, Natalie A, et al.
Publicado: (2017)

Bortezomib/lenalidomide: Interstitial pneumonitis and peripheral neuropathy: case report
Publicado: (2020)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Amyloid A amyloidosis with subcutaneous drug abuse
por: Mendoza, Jair Munoz, et al.
Publicado: (2013)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
por: Ye, Ziqi, et al.
Publicado: (2019)

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer
por: Chaturvedi, Shruti, et al.
Publicado: (2014)

Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients
por: Chaulagain, Chakra P., et al.
Publicado: (2020)

Acupuncture Treatment for Bortezomib-Induced Peripheral Neuropathy: A Case Report
por: Bao, Ting, et al.
Publicado: (2011)

Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy
por: Pero, Maria Elena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r16jurlrp1bq2jq4jrshfhq16d